Who
Jessica Edgar Morris
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Tonix Pharmaceuticals Holding.
In numbers
- Trades disclosed
- 31
- Buys
- 1
- Sells
- 0
- Bought
- $1,257
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 31 Dec 2015
- Last trade
- 24 Feb 2026
- Last filed
- 26 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,012 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,011 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,012 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,011 at $0.00 | filing |
| 25 Feb 2025filed 27 Feb 2025 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,291 at $0.00 | filing |
| 25 Feb 2025filed 27 Feb 2025 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,291 at $0.00 | filing |
| 5 Feb 2025filed 27 Feb 2025 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Code J | —1 at $0.00 | filing |
| 27 Feb 2024filed 29 Feb 2024 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —317,000 at $0.00 | filing |
| 27 Feb 2024filed 29 Feb 2024 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —317,000 at $0.00 | filing |
| 23 Feb 2023filed 24 Feb 2023 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —207,500 at $0.00 | filing |
| 23 Feb 2023filed 24 Feb 2023 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —207,500 at $0.00 | filing |
| 15 Feb 2022filed 17 Feb 2022 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,100,000 at $0.00 | filing |
| 15 Feb 2022filed 17 Feb 2022 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,100,000 at $0.00 | filing |
| 15 Feb 2022filed 17 Feb 2022 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,100,000 at $0.00 | filing |
| 15 Feb 2022filed 17 Feb 2022 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,100,000 at $0.00 | filing |
| 23 Feb 2021filed 25 Feb 2021 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —540,000 at $0.00 | filing |
| 23 Feb 2021filed 25 Feb 2021 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —540,000 at $0.00 | filing |
| 4 May 2020filed 6 May 2020 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —360,000 at $0.00 | filing |
| 4 May 2020filed 6 May 2020 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —360,000 at $0.00 | filing |
| 25 Feb 2020filed 27 Feb 2020 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
News
Tonix Pharmaceuticals Sets 2027 Phase 1 Target For TNX-801 Vaccine CandidateTNXP · rttnews.com · 15 Oct 2026Tonix Pharmaceuticals Begins Building Lyme Disease Drug Facility in Hamilton, MontanaTNXP · matr.net · 12 Oct 2026
0 headlines in the last 90 days name Jessica Edgar Morris; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.